EPS

The defense contractor signals a strategic shift after lost contracts and procurement delays slash its 2027 revenue outlook, even as profits beat expectations.

NervGen Pharma to unveil data showing its drug NVG-291 provides lasting functional gains for chronic spinal cord injury, a major step forward.

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.

With French state backing, Eutelsat secures €1bn to build its next-gen OneWeb LEO constellation, intensifying the global satellite internet race.

With a massive French state-guaranteed financing, Eutelsat is funding a new fleet of 340 Airbus satellites to secure OneWeb's future in the LEO race.

After a challenging 2025, Lennox sets the stage for its March 4 Investor Day, where it will reveal new long-term growth targets to a watchful market.

A new report shows the carbon removal market has the tools to fight climate change, but widespread corporate inaction threatens to strand vital projects.

Fresh off a strategic rebrand and a record-breaking year, Potomac Bancshares is courting investors and cementing its role as a Mid-Atlantic banking leader.

As Home Depot prepares its year-end report, investors weigh a tough consumer market against the firm's big strategic bets on pro customers and digital tools.

After a stellar 2025, Corpay is hitting the road for key investor conferences. Can it convince the market its impressive growth is just the beginning?

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.

Real estate giant KDC is pivoting to power the AI boom, hiring an industry expert to scale its national data center platform amid explosive demand.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

A spike in layoffs to 14-year highs clashes with extreme investor optimism, raising fears of a major market correction on the horizon for 2026.

Waters finalized its $18.8B merger with BD's units, doubling its size. But investor concerns over near-term performance sent shares tumbling.

Universal Corporation appoints Steven Diel, the mind behind its ingredients push, as CFO, signaling a firm commitment to diversification despite headwinds.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

The Middle East healthcare giant posts record profits and a $163M dividend, fueled by aggressive international acquisitions and a major bet on AI technology.